Literature DB >> 33350984

Echinatin effectively protects against NLRP3 inflammasome-driven diseases by targeting HSP90.

Guang Xu1,2, Shubin Fu1,3,4, Xiaoyan Zhan1,2, Zhilei Wang1,5, Ping Zhang1,2, Wei Shi1,3, Nan Qin1,3, Yuanyuan Chen1, Chunyu Wang1, Ming Niu1, Yuming Guo2, Jiabo Wang1, Zhaofang Bai1, Xiaohe Xiao1.   

Abstract

Aberrant activation of NLRP3 inflammasome has been implicated in a variety of pan class="Species">human inflammatory diseases, but currently, no pharmacological NLRP3 inhibitor has been approved. In this study, we showed that echinatin, the ingredient of the traditional herbal medicine licorice, effectively suppresses the activation of NLRP3 inflammasome in vitro and in vivo. Further investigation revealed that echinatin exerts its inhibitory effect on NLRP3 inflammasome by binding to heat-shock protein 90 (HSP90), inhibiting its ATPase activity and disrupting the association between the cochaperone SGT1 and HSP90-NLRP3. Importantly, in vivo experiments demonstrated that administration of echinatin obviously inhibits NLRP3 inflammasome activation and ameliorates LPS-induced septic shock and dextran sodium sulfate-induced (DSS-induced) colitis in mice. Moreover, echinatin exerted favorable pharmacological effects on liver inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis (NASH). Collectively, our study identifies echinatin as a potentially novel inhibitor of NLRP3 inflammasome, and its use may be developed as a therapeutic approach for the treatment of NLRP3-driven diseases.

Entities:  

Keywords:  Immunology; Inflammation; Innate immunity

Mesh:

Substances:

Year:  2021        PMID: 33350984      PMCID: PMC7934863          DOI: 10.1172/jci.insight.134601

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  60 in total

Review 1.  The inflammasomes: guardians of the body.

Authors:  Fabio Martinon; Annick Mayor; Jürg Tschopp
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

2.  Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes.

Authors:  Alvin Lu; Venkat Giri Magupalli; Jianbin Ruan; Qian Yin; Maninjay K Atianand; Matthijn R Vos; Gunnar F Schröder; Katherine A Fitzgerald; Hao Wu; Edward H Egelman
Journal:  Cell       Date:  2014-03-13       Impact factor: 41.582

3.  NLRP3 Phosphorylation Is an Essential Priming Event for Inflammasome Activation.

Authors:  Nan Song; Zhao-Shan Liu; Wen Xue; Zhao-Fang Bai; Qian-Yi Wang; Jiang Dai; Xin Liu; Yi-Jiao Huang; Hong Cai; Xiao-Yan Zhan; Qiu-Ying Han; Hongxia Wang; Yuan Chen; Hui-Yan Li; Ai-Ling Li; Xue-Min Zhang; Tao Zhou; Tao Li
Journal:  Mol Cell       Date:  2017-09-21       Impact factor: 17.970

4.  Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl4-induced liver injury in mice.

Authors:  Yan Lin; Yi Kuang; Kai Li; Shuang Wang; Shuai Ji; Kuan Chen; Wei Song; Xue Qiao; Min Ye
Journal:  Bioorg Med Chem       Date:  2017-08-15       Impact factor: 3.641

5.  Gout-associated uric acid crystals activate the NALP3 inflammasome.

Authors:  Fabio Martinon; Virginie Pétrilli; Annick Mayor; Aubry Tardivel; Jürg Tschopp
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

6.  Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1.

Authors:  Fayyaz S Sutterwala; Yasunori Ogura; Marian Szczepanik; Maria Lara-Tejero; G Scott Lichtenberger; Ethan P Grant; John Bertin; Anthony J Coyle; Jorge E Galán; Philip W Askenase; Richard A Flavell
Journal:  Immunity       Date:  2006-03       Impact factor: 31.745

7.  Carbamazepine promotes specific stimuli-induced NLRP3 inflammasome activation and causes idiosyncratic liver injury in mice.

Authors:  Zhilei Wang; Guang Xu; Xiaoyan Zhan; Youping Liu; Yuan Gao; Nian Chen; Yuming Guo; Ruisheng Li; Tingting He; Xueai Song; Ming Niu; Jiabo Wang; Zhaofang Bai; Xiaohe Xiao
Journal:  Arch Toxicol       Date:  2019-11-01       Impact factor: 5.153

8.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

9.  Glyburide inhibits the Cryopyrin/Nalp3 inflammasome.

Authors:  Mohamed Lamkanfi; James L Mueller; Alberto C Vitari; Shahram Misaghi; Anna Fedorova; Kurt Deshayes; Wyne P Lee; Hal M Hoffman; Vishva M Dixit
Journal:  J Cell Biol       Date:  2009-10-05       Impact factor: 10.539

10.  Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines.

Authors:  Amarjargal Dashdorj; K R Jyothi; Sangbin Lim; Ara Jo; Minh Nam Nguyen; Joohun Ha; Kyung-Sik Yoon; Hyo Jong Kim; Jae-Hoon Park; Michael P Murphy; Sung Soo Kim
Journal:  BMC Med       Date:  2013-08-06       Impact factor: 8.775

View more
  9 in total

1.  Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7-NLRP3 interaction.

Authors:  Qiang Li; Hui Feng; Hongbo Wang; Yinghao Wang; Wenqing Mou; Guang Xu; Ping Zhang; Ruisheng Li; Wei Shi; Zhilei Wang; Zhie Fang; Lutong Ren; Yan Wang; Li Lin; Xiaorong Hou; Wenzhang Dai; Zhiyong Li; Ziying Wei; Tingting Liu; Jiabo Wang; Yuming Guo; Pengyan Li; Xu Zhao; Xiaoyan Zhan; Xiaohe Xiao; Zhaofang Bai
Journal:  EMBO Rep       Date:  2021-12-09       Impact factor: 8.807

2.  Yinzhihuang oral liquid protects against non-alcoholic steatohepatitis via modulation of the gut-liver axis in mice.

Authors:  Shuyu Li; Fangyuan Chen; Yanting Zou; Liuxin Ning; Guangcong Zhang; Shuncai Zhang; Qunyan Yao
Journal:  Ann Transl Med       Date:  2022-06

Review 3.  NLRP3 Inflammasome Pharmacological Inhibitors in Glycyrrhiza for NLRP3-Driven Diseases Treatment: Extinguishing the Fire of Inflammation.

Authors:  Zhilei Wang; Guang Xu; Zhiyong Li; Xiaohe Xiao; Jianyuan Tang; Zhaofang Bai
Journal:  J Inflamm Res       Date:  2022-01-19

4.  Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.

Authors:  Si-Jing Hu; Gang Cheng; Hao Zhou; Qi Zhang; Quan-Long Zhang; Yang Wang; Yi Shen; Chen-Xia Lian; Xue-Qin Ma; Qiao-Yan Zhang; Lu-Ping Qin
Journal:  Molecules       Date:  2022-01-21       Impact factor: 4.411

5.  A Quantitative Systems Pharmacology Platform Reveals NAFLD Pathophysiological States and Targeting Strategies.

Authors:  Daniel E Lefever; Mark T Miedel; Fen Pei; Johanna K DiStefano; Richard Debiasio; Tong Ying Shun; Manush Saydmohammed; Maria Chikina; Lawrence A Vernetti; Alejandro Soto-Gutierrez; Satdarshan P Monga; Ramon Bataller; Jaideep Behari; Vijay K Yechoor; Ivet Bahar; Albert Gough; Andrew M Stern; D Lansing Taylor
Journal:  Metabolites       Date:  2022-06-07

Review 6.  Plant-derived bioactive compounds regulate the NLRP3 inflammasome to treat NAFLD.

Authors:  Qian Huang; Xin Xin; QinMei Sun; Ziming An; Xiaojun Gou; Qin Feng
Journal:  Front Pharmacol       Date:  2022-08-09       Impact factor: 5.988

Review 7.  Pharmacological effects of Chinese medicine modulating NLRP3 inflammasomes in fatty liver treatment.

Authors:  Tingting Liu; Guang Xu; Longxin Liang; Xiaohe Xiao; Yanling Zhao; Zhaofang Bai
Journal:  Front Pharmacol       Date:  2022-09-08       Impact factor: 5.988

Review 8.  The Regulatory Effects of Traditional Chinese Medicine on Ferroptosis.

Authors:  Qian Gao; Xue-Dong Yin; Fan Zhang; Yi-Zhun Zhu; Zhi-Ling Li
Journal:  Oxid Med Cell Longev       Date:  2022-09-19       Impact factor: 7.310

9.  Echinatin mitigates sevoflurane-induced hippocampal neurotoxicity and cognitive deficits through mitigation of iron overload and oxidative stress.

Authors:  Zilong Xu; Yanqiu You; Qiuqin Tang; Hui Zeng; Tianshou Zhao; Juan Wang; Fujun Li
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.